地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：18771149750
传真：18372041646
邮箱：sales@amyjet.com
艾美捷科技代理Reprocell品牌。
Reprocell 是一家专注于干细胞研究、药物筛选和再生医学的生物技术公司，提供多种创新的细胞培养技术和产品，支持从基础研究到临床应用的全流程开发，应用于再生医学、药物发现、基础研究、临床应用。Reprocell公司的产品组合支持干细胞研究和3D生物工程组织开发。Reprocell采用先进的干细胞培养和分化技术，确保产品的高质量和一致性；提供基于干细胞的药物筛选平台，支持高通量药物发现和毒性测试；提供灵活的定制细胞培养和药物筛选服务，满足客户需求。
Reprocell公司主要产品包括：
（1）干细胞产品：提供多种干细胞系，包括诱导多能干细胞（iPSCs）、胚胎干细胞（ESCs）和成体干细胞。
（2）细胞培养试剂：提供高质量的细胞培养基、生长因子和细胞培养试剂盒。
（3）药物筛选平台：提供基于干细胞的药物筛选平台，用于高通量药物发现和毒性测试。
（4）定制服务：根据客户需求，提供定制化的细胞培养和药物筛选服务。
艾美捷科技代理Celscientific品牌。
Celscientific是一家专注于细胞培养和生物试剂的公司，提供高质量的细胞培养产品、生物试剂和实验室耗材，支持生命科学研究和生物技术开发。Celscientific采用先进的生产和质控技术，确保产品的高质量和一致性；产品广泛应用于细胞生物学、分子生物学和生物技术研究。提供灵活的定制细胞培养和生物试剂开发服务，满足客户需求。
Celscientific公司主要产品与服务包括：
（1）细胞培养产品：提供多种细胞培养基、血清、生长因子和细胞培养试剂盒。
（2）生物试剂：提供多种生物试剂，包括抗体、酶、蛋白质和核酸。
（3）实验室耗材：提供高质量的实验室耗材，如培养皿、离心管、移液器等。
（4）定制服务：根据客户需求，提供定制化的细胞培养和生物试剂开发服务。
< " data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Celscientific品牌"> 艾美捷科技代理Celscientific品牌
艾美捷科技代理Nu-Tek Biosciences品牌。
Nu-Tek BioSciences 为生物技术和制药公司开发和生产蛋白胨及蛋白质水解物。Nu-Tek BioSciences产品组合广泛应用于多种领域，从哺乳动物细胞培养到工业发酵，这些产品还用于制造无过敏原的益生菌和其他高价值的营养产品。Nu-Tek BioSciences 正在为蛋白胨、水解物和酵母提取物的制造设定更高标准。作为行业领先的解决方案制造商，Nu-Tek 提供卓越的客户服务和性能优化的细胞营养解决方案。公司利用其符合 ISO 和 GMP 标准的设施，采用专有工艺进行生产，几乎可以生产任何所需的蛋白胨或水解物，这使得 Nu-Tek 成为定制制造的首选。经过行业领先的制药和生物技术公司的审核和认可，Nu-Tek持续改进产品质量。
< " data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Nu-Tek Biosciences品牌"> 艾美捷科技代理Nu-Tek Biosciences品牌
艾美捷科技代理BBI Solutions品牌诊断原料。
BBI Solutions的产品范围广泛，包括人的抗原、抗体、血清、血浆和临床化学酶等优质原料，还生产世界知名的ELISA试剂盒、生物传感器的标签、黄金纳米粒子和葡萄糖氧化酶等。BBI Solutions提供一系列专业的服务，包括抗体开发、抗体制造、抗原定制、金共轭化等。其独特的抗体开发、侧向流动试验开发和制造服务组合，能够支持客户从概念到商业化的全过程。BBI Solutions拥有专业的研究团队和完善的生产和质控流程，确保了公司产品的高品质。其提供的技术支持涵盖了产品的应用验证、配对使用抗体的推荐等方面，为客户提供了全方位的技术保障。BBI Solutions公司提供试剂专用酶：辣根过氧化物酶、谷氨酸脱氢酶、碱性磷酸酶、尿素酶、胆固醇酯酶，聚链霉亲和素，人源蛋白，单克隆抗体，金纳米颗粒等。
<<< " data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理BBI Solutions品牌诊断原料"> 艾美捷科技代理BBI Solutions品牌诊断原料
<艾美捷科技代理VIDIA品牌全系列产品
VIDIA Ltd.是一家捷克私营生物技术公司，创立于1991年，是体外诊断试剂（IVD）生产商，产品应用于人类医学诊断和环境监测领域。自2003年起，公司已通过ISO 9001和ISO 13485认证。所有IVD产品均获得CE认证。其产品设计具有高稳定性和长保质期，且易于使用。
▍VIDIA公司产品线
● ELISA-VIDITEST™ 免疫酶联检测试剂盒：基于酶联免疫吸附法，具有抗体定量/半定量/定性分析、鞘内抗体合成测定以及抗体亲和力评估的检测功能。
● MONO-VIDITEST™ 单次检测盒：基于间接ELISA方法，用于测定样品中特异性抗体的含量。这些试剂盒旨在对血清、血浆、脑脊液和滑膜液样本中的 IgA、IgM 和 IgG 类抗体进行定量/半定量评估。
● LIA-VIDITEST：基于硝酸纤维素膜条的酶联线性免疫印迹法，单次运行即可并行检测多个样本的 IgM 和 IgG 抗体，经验证适用于全自动或半自动的 RoboBlot、BeeBlot、B20 分析仪。
● RAPID-VIDITEST 快速检测试剂盒：诊断型快速色谱免疫分析法，操作简便，结果易判读，可定性检测多种病毒、细菌、寄生虫的抗原。
● IF-VIDITEST：应用于多种感染的血清学诊断，具有高灵敏度与高特异性，操作流程简便的特点。
▍VIDIA部分产品列表
| 品名 | 规格 | 货号 |
| ELISA-VIDITEST anti-complement factor H | 48 wells quantitative | ODZ-166 |
| ELISA-VIDITEST EDUCO Diagnostic | 96 wells 6 doublestrips | ODZ-191 |
| CMV - CI combi r.t.u. | 1 ml | ODZ-264 |
| VZV - CI combi r.t.u. | 1 ml | ODZ-289 |
| HSV-1 - CI nativ r.t.u. | 1 ml | ODZ-314 |
| HSV-2 - CI nativ r.t.u. | 1 ml | ODZ-315 |
| CMV - CI nativ conc. | 0,5 mg | ODZ-319/05 |
| VZV - CI nativ conc. | 0,1 mg | ODZ-320 |
| HSV-1 - CI nativ conc. | 0,1 mg | ODZ-321 |
| HSV-2 - CI nativ conc. | 0,1 mg | ODZ-322 |
| Control - CI r.t.u. (pro CMV, VZV) | 1 ml | ODZ-365 |
| Control - CI r.t.u. (pro HSV-1, HSV-2) | 1 ml | ODZ-366 |
| ELISA-VIDITEST Bisphenol A | 96 wells quantitative | ODZ-041 |
| ELISA-VIDITEST Microcystin-LR | 96 wells quantitative | ODZ-165 |
| ELISA-VIDITEST pNF-H (Neurofilament-H) | 96 wells quantitative | ODZ-437 |
| ELISA-VIDITEST anti-HSV1+2 IgG | 96 wells semiquantitative | ODZ-169 |
| ELISA-VIDITEST anti-HSV1+2 IgM | 96 wells semiquantitative | ODZ-234 |
| ELISA-VIDITEST anti-HSV1+2 IgA | 96 wells semiquantitative | ODZ-283 |
| MONO-VIDITEST anti-HSV IgG | 12 tests | KZ-140-12 |
| MONO-VIDITEST anti-HSV IgM | 12 tests | KZ-141-12 |
| ELISA-VIDITEST anti-EBNA-1 EBV IgG, doublestrip | 96 wells semiquantitative | ODZ-015 |
| ELISA-VIDITEST anti-EBNA-1 EBV IgG | 96 wells semiquantitative | ODZ-001 |
| ELISA-VIDITEST anti-EBNA-1 EBV IgM | 96 wells semiquantitative | ODZ-002 |
| ELISA-VIDITEST anti-VCA EBV IgG | 96 wells semiquantitative | ODZ-265 |
| ELISA-VIDITEST anti-VCA EBV IgG (CSF) | 96 wells quantitative | ODZ-084 |
| ELISA-VIDITEST anti-VCA EBV IgG and IgG avidity | 96 wells semiquantitative | ODZ-175 |
| ELISA-VIDITEST anti-VCA EBV IgM | 96 wells semiquantitative | ODZ-005 |
| ELISA-VIDITEST anti-VCA EBV IgA | 96 wells semiquantitative | ODZ-096 |
| ELISA-VIDITEST anti-EA (D) EBV IgG | 96 wells semiquantitative | ODZ-006 |
| ELISA-VIDITEST anti-EA (D) EBV IgM | 96 wells semiquantitative | ODZ-007 |
| ELISA-VIDITEST anti-EA (D) EBV IgA | 96 wells semiquantitative | ODZ-254 |
| MONO-VIDITEST anti-VCA EBV IgG | 12 tests | KZ-100-12 |
| MONO-VIDITEST anti-VCA EBV IgM | 12 tests | KZ-101-12 |
| MONO-VIDITEST anti-VCA EBV IgA | 12 tests | KZ-102-12 |
| MONO-VIDITEST anti-VCA EBV IgG avidita | 12 tests | KZ-103-12 |
| MONO-VIDITEST anti-EBNA-1 EBV IgG | 12 tests | KZ-110-12 |
| MONO-VIDITEST anti-EBNA-1 EBV IgM | 12 tests | KZ-111-12 |
| ELISA-VIDITEST anti-CMV IgG (CSF) | 96 wells quantitative | ODZ-102 |
| ELISA-VIDITEST anti-CMV IgG and IgG avidity | 96 wells semiquantitative | ODZ-177 |
| ELISA-VIDITEST anti-CMV IgM | 96 wells semiquantitative | ODZ-402 |
| ELISA-VIDITEST anti-CMV IgA | 96 wells semiquantitative | ODZ-164 |
| ELISA-VIDITEST anti-VZV IgG | 96 wells semiquantitative | ODZ-168 |
| ELISA-VIDITEST anti-VZV IgG (CSF) | 96 wells quantitative | ODZ-087 |
| ELISA-VIDITEST anti-VZV IgG and IgG avidity | 96 wells semiquantitative | ODZ-233 |
| ELISA-VIDITEST anti-VZV IgM | 96 wells semiquantitative | ODZ-197 |
| ELISA-VIDITEST anti-VZV IgA | 96 wells semiquantitative | ODZ-284 |
| MONO-VIDITEST anti-EA(D) EBV IgG | 12 tests | KZ-120-12 |
| MONO-VIDITEST anti-EA(D) EBV IgM | 12 tests | KZ-121-12 |
<艾美捷科技代理Stereospecific Detection Technologies品牌全系列产品
Stereospecific Detection Technologies (SDT)是一家专注于免疫分析、核酸杂交和免疫组织化学领域高性能试剂开发与生产的公司。Stereospecific Detection Technologies (SDT)生产用于ELISA、印迹(Blotting)、DNA/RNA杂交和IHC应用中超灵敏检测的试剂，Stereospecific Detection Technologies (SDT)提供三大类特种产品，以及各种免疫分析支持（辅助）试剂：多聚HRP和多聚GOD偶联物；多聚HRP稀释液、封闭剂和稳定剂；TMB 底物以及免疫分析辅助试剂。
▎Stereospecific Detection Technologies产品线
● Poly-HRP：Poly-HRP偶联物是Stereospecific Detection Technologies (SDT)独家生产的、用于超灵敏检测的独特产品。Stereospecific Detection Technologies (SDT)生产通用的：链霉亲和素-Poly-HRP、重组蛋白A-Poly-HRP、重组蛋白A/G-Poly-HRP偶联物，山羊抗小鼠IgG-Poly-HRP、兔抗小鼠IgG-Poly-HRP、山羊抗兔IgG-Poly-HRP、小鼠单克隆抗人IgG(H链, γ链特异性)-Poly-HRP和抗人 IgM (H链, µ链特异性)-Poly-HRP偶联物。
● PolyGOD：广泛应用在电化学免疫传感器、葡萄糖和氧传感、单层和多层薄膜免疫检测、过氧化物隧道免疫检测系统以及免疫组织化学(IHC)应用等领域。
● 专用辅助试剂：Stereospecific Detection Technologies (SDT)开发了用于制造高度浓缩、稳定且可通过0.2/0.45 µm滤膜过滤的酪蛋白胶体缓冲液，无生物素稀释液/封闭剂等特色产品。
● TMB底物及检测支持试剂：TMB底物包括超灵敏液态TMB（s(HS)TMB）、沉淀型膜用 TMB（p(HS)TMB）。检测支持试剂包括：浓缩的10% BSA溶液；HAMA 封闭剂；通用封闭剂；异嗜性抗体封闭剂。
▎Stereospecific Detection Technologies部分产品列表
| 品名 | 货号 | 规格 |
| Streptavidin-PolyHRP20 | #SP20C | 0.5 mg;1 mg;10 mg;25 mg |
| Streptavidin-PolyHRP40 | #SP40C | 0.5 mg;1 mg;10 mg;25 mg |
| Streptavidin-PolyHRP80 | #SP80C | 0.5 mg;1 mg;10 mg;25 mg |
| Mouse monoclonal anti-human IgG (H, γ-chain specific) DY649 labeled | #MAHG-DY649 | 0.5 mg;1 mg |
| Mouse monoclonal anti-human IgG (H, γ-chain specific) PolyHRP40 | #MAHGP-DY549C | 0.5 mg;1 mg |
| Giant Premium PolyStreptAvidin | #GPPSA | 1 mg;10 mg;25 mg;50 mg |
| Streptavidin-HRP, monomeric, cryopreserved | #SM1C | 1 mg;10 mg;25 mg |
| High Load StrongZyme™ Streptavidin-(Poly)HRP | #HL-SZ-SA | 1 mg;10 mg;25 mg |
| AmpliShine™ SA-PolyPE High Sensitivity Conjugate | #SAPE-AS | 1 mg |
| SA-(mono)PE IHC Grade Conjugate | #SAPE-M | 1 mg |
| recombinant Protein A - PolyHRP20 | #AP20C | 0.5 mg;1 mg;10 mg;25 mg |
| recombinant Protein A/G PolyHRP40 | #AGP40C | 0.5 mg;1 mg;10 mg |
| enhanced recombinant Protein A/G-PolyHRP40 | #AGP40C-WB | 0.5 mg;1 mg;10 mg |
| Goat anti-Mouse IgG (H+L)-PolyHRP40 | #GAMP40C | 0.5 mg;1 mg;10 mg;25 mg |
| Enhanced Streptavidin-PolyHRP Conjugate Stabilizer HTS-E | #SA1-HTS-E | 50 ml;100 ml;250 ml;500 ml;1000 ml;10 L |
| Streptavidin-PolyHRP Conjugate Stabilizer RHT(Real-Time High Temperature)synthetic | #SA3-RHT | 50 ml;100 ml;250 ml;500 ml;1000 ml;10 L |
| Antibody/Antigen (PolyHRP) Conjugate Stabilizer | #AA1 | 50 ml;100 ml;250 ml;500 ml;1000 ml;10 L |
| ep(HS)TMB-mA, enhanced stable precipitating 1-component TMB | #epTMB-mA | 30 ml；60 ml;125 ml;250 ml;500 ml;1000 ml |
| Stop/Elution Reagent for stopping | #SER | 65 ml；100 ml;250 ml;500 ml;1000 ml |
| Blocker of Human Anti-Mouse IgG Antibodies (HAMA) | #HAMAB | 10mg；100mg |
| 10% BSA, Ultra-pure, biotin and IgG free | #BSA1 | 10 ml;50 ml;100 ml;250 ml;500 ml;1000 ml |
| 10% BSA, trace biotin and IgG | #BSA2 | 10 ml;50 ml;100 ml;250 ml;500 ml;1000 ml |
| Binding/Coating Buffer 10X Concentrate | #BBC | 100 ml;250 ml;500 ml;1000 ml;1 L;10 L |
| Phosphate Buffered Saline (PBS) 10X Concentrate | #PBSC | 100 ml;250 ml;500 ml;1000 ml;1 L;10 L |
| Wash Buffer 20X Concentrate | #WBC-x20 | 100 ml;250 ml;500 ml;1000 ml;1 L;10 L |
| Substrate Buffer 10X Concentrate | #SBC | 100 ml;250 ml;500 ml;1000 ml;1 L;10 L |
| 5-Bromo-5-Nitro-1,3-Dioxane | #BND-D | 5 g;10 g;20 g;50 g;100 g;1000 g |
艾美捷科技代理Smartox Biotechnology品牌。
Smartox Biotechnology主要提供肽类药物开发、神经科学、离子通道研究领域相关研究工具。
Smartox Biotechnology技术优势包括：
（1）高纯度肽合成: 采用先进的合成技术，确保肽类药物的高纯度和高活性。
（2）离子通道研究: 在离子通道调节剂开发方面具有深厚的技术积累。
（3）定制化服务: 提供灵活的定制肽合成和药物开发服务，满足客户需求。应用于神经科学研究: 研究神经系统疾病和开发新疗法；药物开发: 用于开发针对离子通道和神经受体的新药；生物医学研究: 用于研究肽类药物在生物医学中的应用。
Smartox Biotechnology公司主要业务包括：
（1）肽类药物：提供多种高纯度的肽类药物，用于神经科学和药物开发。
（2）离子通道调节剂：开发针对离子通道的调节剂，用于研究和治疗神经系统疾病。
（3）定制肽合成：根据客户需求，提供定制化的肽合成服务。
（4）药物开发服务：提供从肽设计到临床前开发的全流程服务。
<< " data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Smartox Biotechnology品牌"> 艾美捷科技代理Smartox Biotechnology品牌
艾美捷科技代理SYnAbs品牌抗体。
SYnAbs公司针对免疫原性较差的化合物和复杂抗原进行开发，其抗体产品线范围包括：针对跨膜蛋白（GPCR、离子通道、转运蛋白）、类固醇、小分子、毒素、脂质和
多糖（针对真菌和细菌）的单克隆抗体。为了应对针对半抗原和膜蛋白产生创新单克隆抗体的挑战，SYnAbs公司开发了一整套技术，结合了：
（1）通过专有技术进行创新抗原设计SYnDNA载体、SYnCell同基因细胞系和特殊佐剂；
（2）专有大鼠LOU物种、野生型、敲除型和多种转基因物种（包括 ATX-Gx 转基因小鼠平台）的多物种免疫；
（3）独特的免疫策略打破免疫耐受并触发特定表位；
（4）稀有B细胞群的选择和分离。
部分单克隆抗体：
Rat anti-human CD2 Siplizumab (LO-CD2a/BTI-322)
Mouse anti-human chemokine receptor
Rat anti-Valproic acid hapten,Rat anti-galactomannan
IgG2b kappa rat anti-His tag (N-ter & C-ter)
IgG1 rat anti-human IgG4
IgG1 kappa rat anti-dinitrophenyl hapten
创新型一抗：
（1）高价值一抗针对复杂和小分子的一抗
（2）同型对照和不相关抗体（抗DNP）
大量二抗：SYnAbs公司为生物技术、制药和体外诊断公司提供大量二抗单克隆抗体目录（超过一百种二抗免疫球蛋白）。
< " data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理SYnAbs品牌抗体"> 艾美捷科技代理SYnAbs品牌抗体
<| 产品名称 | 货号 | 化学式 | 分子量 | CAS# |
| 2,5-Anhydro-6-azido-6-deoxy-1,3-O-isopropylidene-D-glucitol | S20031 | C9H15N3O4 | 229,23 | N/A |
| 4-Azido-4-deoxy-1,6:2,3-dianhydro-β-D-mannopyranose | S97085 | C7H9N3O2 | 167,17 | N/A |
| Methyl-3,6-anhydro-7-azido-2,7-dideoxy-4,5-O-isopropylidene-D-alloheptonate | S10191 | C11H17H3O5 | 271,27 | N/A |
| 1,4-Anhydro-3-azido-2-O-benzoyl-3-deoxy-D-xylitol | S10192 | C12H13N3O4 | 263,25 | N/A |
| 1,4-Anhydro-2-azido-3-O-benzoyl-2-deoxy-D-arabitol | S10189 | C12H13N3O4 | 263,25 | N/A |
| 2-Azido-2-deoxy-1,4;3,6-dianhydro-D-glucitol | S03293 | C6H9N3O3 | 171,15 | N/A |
| 6-Azido-6-deoxy-1,2,3,4-tetra-O-acetyl-α,β-D-galactopyranose | S05174 | C14H19N3O9 | 373,32 | N/A |
| 6-Azido-6-deoxy-1,2,3,4-tetra-O-acetyl-α,β-L-galactopyranose | S02174 | C14H19N3O9 | 373,32 | N/A |
| DIBMA free acid | D-20054 | N/A | N/A | N/A |
| DIBMA monosodium salt | D-20055 | N/A | N/A | N/A |
| Glyco-DIBMA | D-20056 | N/A | N/A | N/A |
| n-Octyl α-D-glucopyranoside (aOG) > 99% highly purified | D97011 | C14H28O6 | 292,38 | 29781-80-4 |
| Methyl 6-O-(-n-heptylcarbamoyl)-α-D-glucopyranoside (HECAMEG) | D20034 | C15H29NO7 | 335,4 | 115457-83-5 |
| n-Hexyl β-D-glucopyranoside > 99% highly purified | D99014 | C12H24O6 | 264,4 | 59080-45-4 |
| n-Heptyl β-D-glucopyranoside (HeptG) > 99% highly purified | D07033 | C13H26O6 | 278,4 | 78617-12-6 |
| n-Octyl β-D-glucopyranoside (OG) > 99% highly purified | D97001 | C14H28O6 | 292,38 | 29836-26-8 |
| n-Octyl β-D-glucopyranoside (OG-C) > 99,5% for crystallography | D97001-C | C14H28O6 | 292,38 | 29836-26-8 |
| n-Nonyl β-D-glucopyranoside (NG) > 99% highly purified | D99011 | C15H30O6 | 306,40 | 69984-73-2 |
| n-Nonyl β-D-glucopyranoside (NG-C) > 99,5% for crystallography | D99011-C | C15H30O6 | 306,40 | 69984-73-2 |
| n-Decyl β-D-glucopyranoside (DG) > 99% highly purified | D99006 | C16H32O6 | 320,43 | 58846-77-8 |
| n-Undecyl β-D-glucopyranoside (UDG) > 99% highly purified | D11023 | C17H34O6 | 334,4 | 70005-86-6 |
| n-Dodecyl β-D-glucopyranoside (DDG) > 99% highly purified | D99007 | C18H36O6 | 348,5 | 59122-55-3 |
| 4-trans-(4-trans-Propylcyclohexyl)-cyclohexyl α-maltoside > 99% (t-PCCαM) | D99019-C | C27H47O11 | 547,67 | N/A |
| n-Dodecyl α-maltoside (αDDM) > 99% highly purified | D99020 | C24H46O11 | 510,63 | 116183-64-3 |
| n-Hexyl β-maltoside (HexM) > 99% highly purified | D20018 | C18H34O11 | 426,4 | 870287-95-9 |
| n-Heptyl β-maltoside (HeptM) > 99% highly purified | D14001 | C19H36O11 | 440,48 | N/A |
| n-Octyl β-maltoside (OM) > 99% highly purified | D20020 | C20H38O11 | 454,4 | 82494-08-4 |
| n-Nonyl β-maltoside (NM) > 99% highly purified | D20015 | C21H40O11 | 468,41 | 106402-05-5 |
| n-Nonyl β-maltoside (NM-C) > 99,5% for crystallography | D20015-C | C21H40O11 | 468,41 | 106402-05-5 |
| n-Decyl β-maltoside (DM) > 99% highly purified | D99003 | C22H42O11 | 482,6 | 82494-09-5 |
| n-Decyl β-maltoside (DM-C) > 99,5% for crystallography | D99003-C | C22H42O11 | 482,6 | 82494-09-5 |
| n-Undecyl β-maltoside (UDM) > 99% highly purified | D99012 | C23H44O11 | 496,6 | 253678-67-0 |
| n-Undecyl β-maltoside (UDM-C) > 99,5% for crystallography | D99012-C | C23H44O11 | 496,6 | 253678-67-0 |
| n-Dodecyl β-maltoside (DDM-C) > 99,5% for crystallography | D97002-C | C24H46O11 | 510,63 | 69227-93-6 |
| n-Tridecyl β-maltoside (TDM) > 99% | D20016 | C25H48O11 | 524,6 | 93911-12-7 |
| n-Tridecyl β-maltoside (TDM-C) > 99,5% for crystallography | D20016-C | C25H48O11 | 524,6 | 93911-12-7 |
| n-Tetradecyl β-maltoside (TeDM-C) > 99,5% for crystallography | D20028-C | C26H50O11 | 538,6 | 18449-82-6 |
| n-Pentadecyl β-maltoside (PDM-C) > 99,5% for crystallography | D20040-C | C27H52O11 | 552,35 | N/A |
| n-Hexadecyl β-maltoside (HeDM) > 99,5% | D20029-C | C28H54O11 | 566,72 | 98064-96-1 |
| n-Dodecyl β-maltoside (DDM) > 99% highly purified | D97002 | C24H46O11 | 510,63 | 69227-93-6 |
| Isopropyl 1-thio-β-D-galactopyranoside (IPTG) | S02122 | C9H18O5 | 238,30 | 367-93-1 |
| n-Heptyl 1-thio-β-D-glucopyranoside (HTG) > 99% highly purified | D99013 | C13H26O5S | 294,4 | 85618-20-8 |
| n-Octyl 1-thio-β-D-glucopyranoside (OTG) > 99% highly purified | D20014 | C14H28O5S | 308,44 | 85618-21-9 |
| n-Nonyl 1-thio-β-D-glucopyranoside (NTG-C) > 99,5% highly purified | D14038-C | C15H30O5S | 322,4 | 98854-15-0 |
| n-Decyl 1-thio-β-D-glucopyranoside (DTG) > 99% highly purified | D20021 | C16H32O5S | 336,4 | 98854-16-1 |
| n-Dodecyl 1-thio-β-maltoside (DDTM-C) > 99,5% highly purified | D20022-C | C24H46O10S | 526,6 | 148565-58-6 |
| n-Heptyl 1-thio-β-D-glucopyranoside (HTG-C) > 99,5% highly purified | D99013-C | C13H26O5S | 294,4 | 85618-20-8 |
| n-Octyl 1-thio-β-D-glucopyranoside (OTG-C) > 99,5% highly purified | D20014-C | C14H28O5S | 308,44 | 85618-21-9 |
| MEGA-8 (N-Octanoyl-N-methylglucamin) | D98004 | C15H31NO6 | 321,4 | 85316-98-9 |
| MEGA-9 (N-Nonanoyl-N-methylglucamin) | D99005 | C16H33NO6 | 335,4 | 85261-19-4 |
| MEGA-10 (N-Decanoyl-N-methylglucamin) | D99008 | C16H33NO6 | 335,4 | 85261-19-4 |
| 1-O-(n-Octyl)-tetraethyleneglycol (C8E4) | D20038 | C16H34O5 | 306,44 | 19327-39-0 |
| 1-O-(n-Decyl)-hexaethyleneglycol (C10E6) | D20041 | C22H46O7 | 422,60 | 5168-89-8 |
| 1-O-(n-Decyl)-nonaethyleneglycol (C10E9) | D20033 | C28H58O10 | 554,75 | 26183-52-81 |
| 1-O-(n-Dodecyl)-tetraethyleneglycol (C12E4) | D20035 | C20H42O5 | 362,54 | 5274-68-0 |
| 1-O-(n-Dodecyl)-octaethyleneglycol (C12E8) | D20039 | C28H58O9 | 538,75 | 3055-98-9 |
| 1-O-(n-Dodecyl)-nonaethyleneglycol (C12E9) | D20032 | C30H62O10 | 582,81 | 3055-99-0 |
| 1-O-(n-Dodecyl)-decaethyleneglycol (C12E10) | D20031 | C32H66O11 | 626,86 | 6540-99-4 |
| 1-O-(n-Tridecyl)-octaethyleneglycol (C13E8) | D20030 | C29H60O9 | 552,78 | 9043-30-5 |
| N,N-Dimethyl-n-dodecylamine-N-oxide (LDAO) | D71111 | C14H31NO | 229,4 | 1643-20-5 |
| Sucrose monolaurate (SUMOL) | S98001 | C24H44NO12 | 524,6 | 25339-99-5 |
| Monoolein (1-O-Oleoyl-rac-glycerol) | D20036 | C21H40O4 | 356,5 | 111-03-5 |
| 3-[(3-Cholamidopropyl)-dimethylammonio]-1-propane sulfonate | D99009 | C32H58N2O7S | 614,89 | 75621-03-3 |
| 3-[(3-Cholamidopropyl)-dimethylammonio]-2-hydroxy-1-propane sulfonate | D99010 | C32H58N2O8S | 630,87 | 82473-24-3 |
| n-Nonyl-phosphocholine (C9-PC) Purity > 99% | S10197 | C14H32NO4P | 309,38 | 253678-64-7 |
| n-Decyl-phosphocholine (C10-PC) Purity > 99% | S10195 | C15H34NO4P | 323,41 | 70504-28-8 |
| n-Undecyl-phosphocholine (C11-PC) Purity > 99% | S10196 | C16H36NO4P | 337,4 | 253678-65-8 |
| n-Dodecyl-phosphocholine (C12-PC) Purity > 99% | S10190 | C17H38NO4P | 351,46 | 29557-51-5 |
| n-Tridecyl-phosphocholine (C13-PC) Purity > 99% | S10198 | C18H40NO4P | 365,49 | 85775-42-4 |
| n-Tetradecyl-phosphocholine (C14-PC) Purity > 99% | S10194 | C19H42NO4P | 379,51 | 77733-28-9 |
| n-Pentadecyl-phosphocholine (C15-PC) Purity > 99% | S10199 | C20H44NO4P | 393,54 | 146801-07-2 |
| n-Hexadecyl-phosphocholine (C16-PC) Purity > 99% | S01241 | C21H46NO4P | 407,57 | 58066-85-6 |
| α-D-Galactopyranose-phosphate di-potassium salt dihydrate | P0001 | C6H11K2O9P. 2H2O | 372,36 | 19046-60-7 |
| α-D-Glucopyranose-phosphate di-potassium salt dihydrate | P0002 | C6H11K2O9P. 2H2O | 372,36 | 5996-14-5 |
| α-D-Mannopyranose-phosphate di-potassium salt dihydrate | P0003 | C6H11K2O9P. 2H2O | 372,36 | 71888-67-0 |
| N-Acetyl-D-galactosamine (2-Acetamido-2-deoxy-D-galactose, GalNAc) | S96001 | C8H15NO6 | 221,21 | 1811-31-0 |
| N-Acetyl-D-glucosamine (2-Acetamido-2-deoxy-D-glucose, GlcNAc) | S93002 | C8H15NO6 | 221,21 | 7512-17-6 |
| 2-Acetamido-2-deoxy-β-D-glucopyranosylamin | S98003 | C8H16N2O5 | 220,21 | 18615-50-4 |
| N-Acetyl-D-mannosamine x H2O (2-Acetamido-2-deoxy-D-mannose monohydrate, D-ManAc x H2O) | S94004 | C8H17NO7 | 239,23 | 7772-94-3 |
| 1,3,4,6-tetra-O-acetyl-β-D-GlcNAc (2-Acetamido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose) | S94005 | C16H23NO10 | 389.36 | 7772-79-4 |
| 3,4,6-tri-O-acetyl-β-D-GlcNAc azide (2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl azide) | S96006 | C14H20N4O8 | 372,34 | 6205-69-2 |
| 3,4,6-tri-O-acetyl-α-D-GlcNAc chlorid (2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chlorid) | S97007 | C14H20CINO8 | 366,80 | 3068-34-6 |
| 1,3,4,6-tetra-O-acetyl-α-D-glucosamine x HCl (2-Amino-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-glucopyranose HCl) | S00116 | C14H22CINO9 | 383,79 | N/A |
| Allyl 2-acetamido-2-deoxy-α-D-glucopyranoside | S96008 | C11H19NO6 | 261,28 | 54400-75-8 |
| Allyl 2-acetamido-2-deoxy-β-D-glucopyranoside | S96009 | C11H19NO6 | 261,28 | 54400-77-0 |
| Allyl α-D-galactopyranoside | S96010 | C9H16O6 | 220,22 | 48149-72-0 |
| Allyl α-D-glucopyranoside | S98011 | C9H16O6 | 220,22 | 7464-56-4 |
| Allyl β-D-glucopyranoside | S98012 | C9H16O6 | 220,22 | 34384-797 |
| Allyl α-D-mannopyranoside | S11118 | C9H16O6 | 220,22 | 41308-76-3 |
| Allyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside | S98013 | C30H34O6 | 490,60 | N/A |
| 1-Amino-1-deoxy-β-D-galactose (β-D-Galactopyranosylamine) | S99102 | C6H13NO5 | 179,17 | 50444-86-5 |
| 1,6-Anhydro-β-D-galactopyranose | S93014 | C6H10O5 | 162,14 | 644-76-8 |
| 1,6:3,4-Dianhydro-2-O-tosyl-β-D-galactopyranose | S97016 | C13H14O6s | 234,25 | 6167-32-4 |
| D-Arabinose | S93017 | C5H10O5 | 150,13 | 28697-53-2 |
| Arbutin (4-Hydroxyphenyl b-D-glucopyranoside, synthetic) | S96018 | C12H16O7 | 272,25 | 497-76-7 |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-galactopyranose | S96021 | C14H19N3O9 | 373,32 | N/A |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α,β-D-galactopyranose | S97022 | C14H19N3O9 | 373,32 | N/A |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose | S96024 | C14H19N3O9 | 373,32 | N/A |
| 2-Azido-2-deoxy-1,2‘,3,3‘,4‘,6,6‘-hepta-O-acetyl-α,β-lactose 2-Azido-2-deoxy-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-1,3,6-tri-O-acetyl-α,β-D-glucopyranose | S96025 | C26H35N3O17 | 661,58 | N/A |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-mannopyranose | S97026 | C14H19N3O9 | 373,32 | N/A |
| Benzyl 4,6-O-benzylidene-α-D-GlcNAc | S97027 | C22H25NO6 | 399,45 | 13343-63-0 |
| Benzyl α-D-GlcNAc (Benzyl 2-acetamido-2-deoxy-α-D-glucopyranoside) | S97028 | C15H21NO6 | 311,34 | 13343-62-9 |
| Benzyl α-D-mannopyranoside | S97029 | C13H18O6 | 270,28 | 155548-45-5 |
| Cellobiose | S96030 | C12H22O11 | 342,30 | 528-50-7 |
| 6-Deoxy-1,2:3,4-di-O-isopropylidene-α-D-galactopyranose | S96032 | C12H20O5 | 244,29 | 4026-27-1 |
| 3,4-Di-O-acetyl-L-rhamnal (3,4-Di-O-acetyl-6-deoxy-L-glucal) | S94035 | C10H14O5 | 214.22 | 34819-86-8 |
| 1,4:3,6-Dianhydro-D-mannitol | S97037 | C6H10O4 | 146,15 | 641-74-7 |
| 1,2,3,4-Di-O-isopropylidene-α-D-galactopyranose | S95038 | C12H20O6 | 260.29 | 4064-06-6 |
| 1,2:5,6-Di-O-isopropylidene-α-D-glucofuranose | S00112 | C12H20O6 | 260,29 | 582-52-5 |
| 1,2:5,6-Di-O-isopropylidene-D-mannitol | S95039 | C12H22O6 | 262,31 | 1707-77-3 |
| 2,3:5,6-Di-O-isopropylidene-α-D-mannofuranose | S93040 | C12H20O6 | 260.29 | 14131-84-1 |
| 1,2:3,5-Di-O-isopropylidene-α-D-xylofuranose | S00110 | C11H18O5 | 230,26 | 20881-04-3 |
| D-Fucose (6-Deoxy-D-galactose) | S96042 | C6H12O6 | 164,16 [3615-37-0] | 3615-37-0 |
| L-Fucose (6-Deoxy-L-galactose) | S96043 | C6H12O6 | 164,16 | 2438-80-4 |
| D-Galactosamine x HCl | S95044 | C6H13NO5 x HCl | 215.64 | 1172-03-8 |
| D-Glucosamine x HCl | S93045 | C6H13NO5 x HCl | 215.64 | 66-84-2 |
| L-Glucose | S94046 | C6H12O6 | 180.16 | 921-60-8 |
| 2,3,3’,4,6,6’-Hexa-O-acetyl-lactal | S97036 | N/A | N/A | |
| 1,2-O-Isopropylidene-α-D-glucofuranose | S00113 | C9H16O6 | 220,22 | 18549-40-1 |
| Isopropyl-β-D-thiogalactoside IPTG (lactose based) | S02122-L | C9H18O5S | 238,31 | 367-93-1 |
| Isopropyl-β-D-thiogalactoside IPTG (on plant based) | S02122-P | C9H18O5S | 238,31 | 367-93-1 |
| 3,4-O-Isopropylidene-D-mannitol | S94048 | C9H18O6 | 222,22 | 369-84-4 |
| 1,2-O-Isopropylidene-α-D-xylofuranose | S00111 | C8H14O5 | 190,20 | 20031-21-4 |
| D-Lyxose | S96051 | C5H10O5 | 150,13 | 1114-34-7 |
| L-Lyxose | S96052 | C5H10O5 | 150,13 | 1949-78-6 |
| Maltose monohydrate | S98053 | C12H22O11H2O | 360,32 | 6363-53-7 |
| β-Maltose octaacetate | S98054 | C28H38O19 | 678,63 | 22352-19-8 |
| D-Mannose | S93057 | C6H12O6 | 180.16 | 3458-28-4 |
| L-Mannose | S94058 | C6H12O6 | 180.16 | 10030-80-5 |
| Methyl 4,6-O-benzylidene-β-D-galactopyranoside | S96060 | C14H18O6 | 282,30 | 6988-39-2 |
| Methyl 4,6-O-benzylidene-α-D-glucopyranoside | S97061 | C14H18O6 | 282,30 | 3162-96-7 |
| Methyl 4,6-O-benzylidene-β-D-glucopyranoside | S98062 | C14H18O6 | 282,30 | 6988-39-2 |
| Methyl 6-deoxy-α-L-mannopyranoside (Methyl a-L-rhamnopyranoside) | S96063 | C7H14O5 | 178,19 | 15814-59-2 |
| Methyl α-D-fucopyranoside | S96064 | C7H14O5 | 178,19 | 1128-40-1 |
| Methyl α-L-fucopyranoside | S96065 | C7H14O5 | 178,19 | 14687-15-1 |
| Methyl β-D-galactopyranoside | S96066 | C7H14O6 | 194,18 | 1824-94-8 |
| Methyl β-D-glucopyranoside hemihydrate | S96067 | C7H14O6 | 194,18 | 7000-27-3 |
| Methyl β-D-ribopyranoside | S97068 | C6H12O5 | 164,16 | 17289-61-1 |
| Methyl 2,3,5-tri-O-benzoyl-α-D-arabinofuranoside | S98069 | C27H24O8 | 476,49 | N/A |
| 1,2,3,4,6-Penta-O-acetyl-β-D-galactopyranose | S95072 | C16H22O11 | 390,35 | 4163-60-4 |
| 1,2,3,4,6-Penta-O-acetyl-α-D-mannopyranose | S99070 | C16H22O11 | 390,35 | 4163-65-9 |
| D-Raffinose pentahydrate | S96074 | C18H32O16 5H2O | 594,53 | 17629-30-0 |
| L-Rhamnose monohydrate | S94075 | C6H14O6 | 182.17 | 10030-85-0 |
| D-Ribose | S93076 | C5H10O5 | 150.13 | 50-69-1 |
| L-Ribose | S93077 | C5H10O5 | 150.13 | 24259-59-4 |
| D-Tagatose | S93079 | C6H12O6 | 180.16 | 87-81-0 |
| α-D-Talose | S93080 | C6H12O6 | 180.16 | 2595-98-4 |
| 2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl azide | S96081 | C14H19N3O9 | 373,32 | 13992-26-2 |
| 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide | S96082 | C14H19BrO9 | 411.21 | 3068-32-4 |
| 2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl azide | S96083 | C14H19N3O9 | 373,32 | 13992-25-1 |
| 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide | S94084 | C14H19BrO9 | 411.21 | 572-09-8 |
| 1,3,4,6-Tetra-O-acetyl-β-D-mannopyranose | S97086 | C14H20O10 | 348,31 | 18968-05-3 |
| 2,3,4,6-Tetra-O-acetyl-α-D-mannopyranose | S97087 | C14H20O10 | 348,31 | N/A |
| 1,2,3,5-Tetra-O-acetyl-β-D-ribofuranose | S94088 | C13H18O9 | 318.28 | 13035-61-5 |
| 2,3,4,6-Tetra-O-acetyl-1-thio-β-D-galactopyranose | S94089 | C14H20O9S | 364.37 | N/A |
| 2,3,4,6-Tetra-O-acetyl-1-thio-β-D-glucopyranose | S94090 | C14H20O9S | 364.37 | 19879-84-6 |
| 2,3,4,6-Tetra-O-benzyl-α-D-galactopyranose | S96091 | C34H3606 | 540.66 | 5308-25-7 |
| 2,3,4,6-Tetra-O-benzyl-α-D-glucopyranose | S93092 | C34H3606 | 540.66 | 4132-28-9 |
| 2,3,4,6-Tetra-O-benzyl-α-D-mannopyranose | S96093 | C34H3606 | 540.66 | 61330-61-8 |
| 1-Thio-β-D-galactose sodium salt | S96094 | C6H11NaO5S | 218,21 | 42891-22-5 |
| 1-Thio-β-D-glucose sodium salt dihydrate | S94095 | C6H11NaO5S x 2 H2O | 254.24 | 10593-29-0 |
| 3,4,6-Tri-O-acetyl-D-galactal | S94097 | C12H16O7 | 272.26 | 4098-06-0 |
| D-Turanose (α-D-Glcp(1-3)-D-fructose) | S93100 | C12H22O11 | 342.30 | 547-25-1 |
| D-Xylose | S93101 | C5H10O5 | 150.13 | 58-86-6 |
| 1,6-Anhydro-β-D-glucopyranose (Levoglucosan) | S93015 | C6H10O5 | 162,14 | 498-07-7 |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-glucopyranose | S96023 | C14H19N3O9 | 373,32 | N/A |
我们承诺：
（1）专业的服务：为您提供包括购买咨询、技术支持及实验方案制定在内的全方位服务；
（2）迅捷的货期：利用国际化的物流平台，大大缩短产品从厂家到最终用户的时间；
（3）过硬的品质：确保正品、质量和售后，多年客户积累，口碑保证。
公司简介：
艾美捷科技有限公司经营范围涵盖分子生物学试剂、免疫学试剂、细胞生物学试剂、蛋白质研究试剂、微生物学试剂、化学及生化试剂、材料学试剂、天然提取物、仪器设备等9大门类，累计约10万余种产品，充分满足不同客户的个性化需求；公司代理国外50余种一线品牌试剂，以“高性价比、迅捷的物流速度、专业的技术支持”，让客户充分享受全球化带来的便利；公司还增加了基因编辑、蛋白表达、细胞鉴定等定制项目，大大提升了为客户服务能力。“不忘初心，方得始终”，艾美捷科技将继续秉持“专心、专业、为您”的宗旨，以客户为根本，以诚信为基础，持续地为各界客户提供更加优质的产品和服务。
Glycon Biochemicals GmbH; Glycon Biochem; Glycon; S20031; S97085; S10191; S10192; S10189; S03293; S05174; S02174; D-20054; D-20055; D-20056; D97011; D20034; D99014; D07033; D97001; D97001-C; D99011; D99011-C; D99006; D11023; D99007; D99019-C; D99020; D20018; D14001; D20020; D20015; D20015-C; D99003; D99003-C; D99012; D99012-C; D97002-C; D20016; D20016-C; D20028-C; D20040-C; D20029-C; D97002; S02122; D99013; D20014; D14038-C; D20021; D20022-C; D99013-C; D20014-C; D98004; D99005; D99008; D20038; D20041; D20033; D20035; D20039; D20032; D20031; D20030; D71111; S98001; D20036; D99009; D99010; S10197; S10195; S10196; S10190; S10198; S10194; S10199; S01241; P0001; P0002; P0003; S96001; S93002; S98003; S94004; S94005; S96006; S97007; S00116; S96008; S96009; S96010; S98011; S98012; S11118; S98013; S99102; S93014; S97016; S93017; S96018; S96021; S97022; S96024; S96025; S97026; S97027; S97028; S97029; S96030; S96032; S94035; S97037; S95038; S00112; S95039; S93040; S00110; S96042; S96043; S95044; S93045; S94046; S97036; S00113; S02122-L; S02122-P; S94048; S00111; S96051; S96052; S98053; S98054; S93057; S94058; S96060; S97061; S98062; S96063; S96064; S96065; S96066; S96067; S97068; S98069; S95072; S99070; S96074; S94075; S93076; S93077; S93079; S93080; S96081; S96082; S96083; S94084; S97086; S97087; S94088; S94089; S94090; S96091; S93092; S96093; S96094; S94095; S94097; S93100; S93101; S93015; S96023; 10030-80-5; 10030-85-0; 10593-29-0; 106402-05-5; 106402-05-5; 111-03-5; 1114-34-7; 1128-40-1; 115457-83-5; 116183-64-3; 1172-03-8; 13035-61-5; 13343-62-9; 13343-63-0; 13992-25-1; 13992-26-2; 14131-84-1; 146801-07-2; 14687-15-1; 148565-58-6; 155548-45-5; 15814-59-2; 1643-20-5; 1707-77-3; 17289-61-1; 17629-30-0; 1811-31-0; 1824-94-8; 18449-82-6; 18549-40-1; 18615-50-4; 18968-05-3; 19046-60-7; 19327-39-0; 1949-78-6; 19879-84-6; 20031-21-4; 20881-04-3; 22352-19-8; 24259-59-4; 2438-80-4; 25339-99-5; 253678-64-7; 253678-65-8; 253678-67-0; 253678-67-0; 2595-98-4; 26183-52-81; 28697-53-2; 29557-51-5; 29781-80-4; 29836-26-8; 29836-26-8; 3055-98-9; 3055-99-0; 3068-32-4; 3068-34-6; 3162-96-7; 34384-797; 3458-28-4; 34819-86-8; 3615-37-0; 367-93-1; 367-93-1; 367-93-1; 369-84-4; 4026-27-1; 4064-06-6; 4098-06-0; 41308-76-3; 4132-28-9; 4163-60-4; 4163-65-9; 48149-72-0; 497-76-7; 498-07-7; 50444-86-5; 50-69-1; 5168-89-8; 5274-68-0; 528-50-7; 5308-25-7; 54400-75-8; 54400-77-0; 547-25-1; 572-09-8; 58066-85-6; 582-52-5; 58846-77-8; 58-86-6; 59080-45-4; 59122-55-3; 5996-14-5; 61330-61-8; 6167-32-4; 6205-69-2; 6363-53-7; 641-74-7; 644-76-8; 6540-99-4; 66-84-2; 69227-93-6; 69227-93-6; 6988-39-2; 6988-39-2; 69984-73-2; 69984-73-2; 7000-27-3; 70005-86-6; 70504-28-8; 71888-67-0; 7464-56-4; 7512-17-6; 75621-03-3; 7772-79-4; 7772-94-3; 77733-28-9; 78617-12-6; 82473-24-3; 82494-08-4; 82494-09-5; 82494-09-5; 85261-19-4; 85261-19-4; 85316-98-9; 85618-20-8; 85618-20-8; 85618-21-9; 85618-21-9; 85775-42-4; 870287-95-9; 87-81-0; 9043-30-5; 921-60-8; 93911-12-7; 93911-12-7; 98064-96-1; 98854-15-0; 98854-16-1
<艾美捷科技代理Synthelis Biotech品牌全系列产品
Synthelis Biotech是一家法国公司，专注于蛋白质的生产、纯化与表征，公司致力于助力疫苗、生物制剂、酶、工程蛋白、诊断工具以及高通量分子或配体筛选技术的开发。Synthelis Biotech提供经过验证的蛋白质，其活性和纯度均根据特定应用（候选药物筛选、抗体与疫苗开发、结构生物学、体外诊断、蛋白质载体化）量身定制。Synthelis Biotech专利的无细胞技术使客户能够从不同蛋白家族（GPCRs、离子通道、转运蛋白等）和不同形式（蛋白脂质体、纳米盘、去垢剂溶解形式或可溶形式）中选择合适的蛋白质。凭借其专利技术，Synthelis 能够在数小时内合成各类蛋白质：包括膜蛋白、毒性蛋白、修饰蛋白等，应用于药物筛选、疫苗与抗体开发、结构生物学以及体外诊断等领域。同时可按需进行修饰（荧光或同位素标记、非天然氨基酸掺入、截短或突变形式等）。
▍Synthelis Biotech产品列表
| 分类 | 品名 | Protein | Origin | Format | Reference | Quantity | 分子量 |
| Viral Proteins | E1 | Envelop protein 1 | Hepatitis C virus | Proteoliposome | PL011 | 10µg, 20µg, 50µg, 100µg, 200µg, 500µg | 21 kDa |
| Viral Proteins | E2 | Envelop protein 1 | Hepatitis C virus | Proteoliposome | PL010 | 10µg, 20µg, 50µg, 100µg, 200µg, 500µg | 21 kDa |
| Viral Proteins | N-protein | Nucleocapsid Protein (COVID-19) | SARS-Cov 2 virus | Soluble | S-144 | 10µg, 20µg, 50µg, 100µg, 200µg, 500µg | 47,7 kDa |
| Viral Proteins | F5L | Vaccinia virus major membrane protein | Vaccinia virus | Proteoliposome | PL007 | 10µg, 20µg, 50µg, 100µg, 200µg, 500µg | 39.0 kDa |
| Viral Proteins | HCV p7 | Hepatitis C virus P7 | HCV virus | Proteoliposome | PL042 | 10µg, 20µg, 50µg, 100µg, 200µg, 500µg | 7 kDa |
| GPCRs | APJ/AR | Apelin Receptor | Human | Proteoliposome | PL061 | 10 µg, 50 µg ,100 µg | 44.7 kDa |
| GPCRs | B2R | Bradykinin receptor 2 | Human | Proteoliposome | PL080 | 10 µg, 50 µg ,100 µg | 47.0 kDa |
| GPCRs | BR | Bacteriorhodopsin | Bacteria | Proteoliposome | PL027 | 10 µg, 50 µg ,100 µg | 29.4 kDa |
| GPCRs | CCR1 | C-C chemokine receptor type 1 | Human | Proteoliposome | PL021 | 10 µg, 50 µg ,100 µg | 43.7 kDa |
| GPCRs | CCR2a | C-C chemokine receptor type 2, isoform a | Human | Proteoliposome | PL022 | 10 µg, 50 µg, 100 µg | 44.5 kDa |
| GPCRs | CCR2b | C-C chemokine receptor type 2, isoform b | Human | Proteoliposome | PL023 | 10µg, 20µg,100 µg, 200 µg | 42 kDa |
| GPCRs | CCR5 | C-C chemokine receptor type 5 | Human | Proteoliposome | PL024 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 40 kDa |
| GPCRs | CXCR4 | C-X-C chemokine receptor type 4 | Human | Proteoliposome | PL016 | 10 µg, 50 µg, 100 µg | 43 kDa |
| GPCRs | CXCR4-Detergent | C-X-C chemokine receptor type 4 | Human | Detergent | D016 | 25µg ,100 µg ,500 µg,bulk | 40 kDa |
| GPCRs | GLP1R | Glucagon-like peptide 1 receptor | Human | Proteoliposome | PL067 | 10 µg, 50 µg, 100 µg | 55.5 kDa |
| GPCRs | GPR50 | G-protein coupled receptor 50 | Human | Proteoliposome | PL095 | 10 µg, 50 µg, 100 µg | 67.4 kDa |
| GPCRs | GPR54 | G-protein coupled receptor 54 | Human | Proteoliposome | PL097 | 10 µg, 50 µg ,100 µg | 45.2 kDa |
| GPCRs | HMOP | Mu-type opioid receptor | Human | Proteoliposome | PL025 | - | - |
| GPCRs | MT1 | Melatonin receptor | Human | Proteoliposome | PL028 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 40 kDa |
| GPCRs | RXFP1 | Relaxin receptor 1 | Human | Proteoliposome | PL068 | 10 µg, 50 µg ,100 µg | 89.1 kDa |
| Ion Channels | kir1.1b | ATP-sensitive inward rectifier potassium channel 1 isoform b | Mouse | Proteoliposome | PL031 | 10µg, 20µg,100 µg, 200 µg, 500 µg, bulk | 42.7 kDa |
| Ion Channels | kv1.2 | Potassium voltage-gated channel subfamily A, member 2 | Rat | Proteoliposome | PL037 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 57 kDa |
| Ion Channels | kv1.3 | Potassium voltage-gated channel subfamily A, member 3 | Mouse | Proteoliposome | PL036 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 58 kDa |
| Ion Channels | VDAC1 | Voltage-Dependent Anion Channel 1 | Human | Proteoliposome | PL029 | 10 µg, 50 µg ,100 µg | 30.7kDa |
| Ion Channels | VDAC1 – Detergent | Voltage-Dependent Anion Channel 1 | Human | Detergent | D029 | 10 µg, 50 µg, 100 µg | 30.7kDa |
| Ligands | SDF1a | Stromal cell-derived factor 1 | Human | Soluble | S069 | 10 µg, 50 µg ,100 µg | 10.7 kDa |
| Porins | OEP24 | Outer envelope pore protein 24, chloroplastic | Plant | Proteoliposome | PL040 | 10 µg, 50 µg ,100 µg | 24 kDa |
| Porins | OprF | Outer membrane porin F | Bacteria | Proteoliposome | PL045 | 10 µg, 50 µg, 100 µg | 40 kDa |
| Enzymes | gp91phox (Nox2 subunit) | gp91phox | Human | Proteoliposome | PL008 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 55 kDa |
| Enzymes | KMO | Kynurenine 3-monooxygenase | Human | Proteoliposome | PL005 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 55,8 kDa |
| Enzymes | Nox2, p22 Phox | Cytochrome b-245 light chain | Human | Proteoliposome | PL039 | 10 µg, 50 µg ,100 µg | 23,5 kDa |
| Enzymes | Nox4 | Nox4 | Human | Proteoliposome | PL059 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 67 kDa |
| Enzymes | PORCN | Protein-Cysteine N-palmitoyltransferase porcupine | Human | Proteoliposome | PL006 | 10 µg, 50 µg, 100 µg | 55.5 kDa |
| Enzymes | TF | Tissue factor | Human | Proteoliposome | PL053 | 10µg, 20µg ,50µg, 100 µg , 200µg, 500 µg,bulk | 33 kDa |
| Enzymes | T7 RNA Pol | T7 RNA Polymerase | Bacteriophage T7 | Soluble | S192 | 10 µg, 50 µg, 100µg | 100.1 kDa |
| Enzymes | DsbC | Disulfide bond isomerase | E.coli | Soluble | S197 | customized quantity on request. | 25.4 kDa |
| Receptors | CLDN 18.2 | Claudin 18.2 Protein | Human | Proteoliposome | PL119 | 10 µg, 50 µg, 100 µg | 30 kDa |
| Transcriptional regulators | AROS | Active regulator of SIRT1 | Human | Proteoliposome | S052 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 15,4 kDa |
| Transporters | Bak | Bcl-2 homologous antagonist killer | Human | Proteoliposome | PL038 | 25µg ,100 µg ,500 µg,bulk | 17 kDa |
| Transporters | EspH | Cytoskeleton-modulating effector of enterohaemorrhagic and enteropathogenic Escherichia coli | Bacteria | Proteoliposome | PL051 | 10 µg, 50 µg, 100 µg | 21.9 kDa |
| Transporters | HCV p7 | Hepatitis C virus P7 | Virus | Proteoliposome | PL042 | 25µg ,100 µg ,500 µg,bulk | 7 kDa |
| Transporters | NhaA | Na(+)/H(+) antiporter NhaA | E. coli | Proteoliposome | PL032 | 10 µg, 50 µg, 100 µg | 43.9 kDa |
| Transporters | UCP1 | Mitochondrial brown fat uncoupling protein 1 | Mitochondria | Proteoliposome | PL047 | 10 µg, 50 µg, 100 µg | 35.1 kDa |
地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：18327026838
传真：18327026838
邮箱：sales@amyjet.com
0.1585
